Families, not single products
Both Restylane and RHA are HA filler families with multiple products designed for different planes, indications, and rheologic needs. Restylane is long-established with a broad range; RHA is often positioned around dynamic, expressive areas. Because each contains products spanning different uses, the right clinical question is never "Restylane or RHA?" but "which product, from whichever family, fits this plane and this indication?" — the same rheology-driven selection logic that governs all filler choice.
Same portfolio, shared loyalty
Both families sit within the Galderma portfolio and are associated with its Aspire program, which matters to your loyalty and rebate strategy. Stocking across these families keeps your volume within one portfolio's loyalty ecosystem, which can strengthen your standing there — a relevant consideration alongside the clinical fit when deciding what to carry.
The owner's takeaway
Many practices carry products across HA families precisely to match the right product to each plane and indication, rather than committing to one family as universally superior. The selection is driven by clinical fit and your portfolio/loyalty strategy, not by a family leaderboard. As with all filler, the per-patient product choice belongs to your injectors and follows rheology and indication; your job is building a coherent menu and a sound loyalty position.
What to do
- Stop framing it as family-versus-family. Each is a range; match specific products to specific planes and indications.
- Factor in the shared portfolio and loyalty program when deciding what to stock, since it affects your rebate and loyalty standing.
- Build the menu by clinical fit and portfolio strategy, not by declaring one family superior.
- Leave per-patient product selection to injectors, following rheology and indication.
